Yan Cheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6178465/publications.pdf

Version: 2024-02-01

279487 223531 2,490 47 23 46 h-index citations g-index papers 48 48 48 3530 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction. Acta Pharmacologica Sinica, 2022, 43, 1594-1604.	2.8	7
2	CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway. Chemico-Biological Interactions, 2022, 351, 109747.	1.7	3
3	EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma. Clinical and Translational Medicine, 2022, 12, e722.	1.7	11
4	eEF2K promotes PD-L1 stabilization through inactivating GSK3 \hat{l}^2 in melanoma. , 2022, 10, e004026.		11
5	Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacologica Sinica, 2021, 42, 1180-1189.	2.8	25
6	Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds. Journal of Medicinal Chemistry, 2021, 64, 7544-7554.	2.9	12
7	Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors. Briefings in Bioinformatics, 2021, 22, .	3.2	5
8	Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. Drug Resistance Updates, 2021, 56, 100752.	6.5	35
9	Emerging mechanisms and targeted therapy of ferroptosis in cancer. Molecular Therapy, 2021, 29, 2185-2208.	3.7	134
10	The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B. Frontiers in Pharmacology, 2021, 12, 720619.	1.6	4
11	Inhibition of autophagy with Chloroquine enhanced apoptosis induced by 5-aminolevulinic acid-photodynamic therapy in secondary hyperparathyroidism primary cells and organoids. Biomedicine and Pharmacotherapy, 2021, 142, 111994.	2.5	11
12	UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics, 2020, 10, 1833-1848.	4.6	28
13	PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer. Frontiers in Pharmacology, 2020, 11, 550469.	1.6	21
14	A combinatorial target screening strategy for deorphaning macromolecular targets of natural product. European Journal of Medicinal Chemistry, 2020, 204, 112644.	2.6	8
15	The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. European Journal of Medicinal Chemistry, 2020, 203, 112570.	2.6	45
16	RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKI±2-mediated autophagy. Oncogene, 2020, 39, 6704-6718.	2.6	15
17	Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy. Cell Death and Disease, 2020, 11, 948.	2.7	18
18	DNA Repair Pathways in Cancer Therapy and Resistance. Frontiers in Pharmacology, 2020, 11, 629266.	1.6	172

#	Article	IF	CITATIONS
19	A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone. European Journal of Medicinal Chemistry, 2020, 199, 112421.	2.6	6
20	DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism. Epigenetics and Chromatin, 2019, 12, 59.	1.8	22
21	Effect and mechanism of psoralidin on promoting osteogenesis and inhibiting adipogenesis. Phytomedicine, 2019, 61, 152860.	2.3	23
22	Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacologica Sinica, 2019, 40, 919-928.	2.8	20
23	eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells. Cancer Letters, 2018, 418, 64-74.	3.2	8
24	Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance. Cell Death and Disease, 2018, 9, 490.	2.7	38
25	A G3BP1-Interacting IncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. Cancer Research, 2018, 78, 3484-3496.	0.4	335
26	Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy. Clinical Cancer Research, 2018, 24, 445-459.	3.2	62
27	Suppression of eEF-2K-mediated autophagy enhances the cytotoxicity of raddeanin A against human breast cancer cells in vitro. Acta Pharmacologica Sinica, 2018, 39, 642-648.	2.8	21
28	Differentially expressed circRNAs in melanocytes and melanoma cells and their effect on cell proliferation and invasion. Oncology Reports, 2018, 39, 1813-1824.	1.2	30
29	RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-ΰB pathway. British Journal of Cancer, 2018, 118, 1617-1627.	2.9	48
30	Inhibition of UCHL1 enhances the sensitivity of estrogen receptor negative breast cancer cells to endocrine therapy. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-7-27.	0.0	0
31	Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is Associated with Metastasis and Genome Instability. Theranostics, 2017, 7, 3920-3932.	4.6	44
32	Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol. Frontiers in Pharmacology, 2017, 8, 804.	1.6	17
33	EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes. Theranostics, 2017, 7, 3293-3305.	4.6	199
34	Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas. Theranostics, 2017, 7, 132-143.	4.6	54
35	Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia. Oncotarget, 2016, 7, 43390-43400.	0.8	70
36	High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget, 2016, 7, 9102-9117.	0.8	24

#	Article	IF	CITATIONS
37	Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect. Acta Pharmacologica Sinica, 2016, 37, 1013-1019.	2.8	92
38	Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase. Cancer Research, 2016, 76, 5743-5755.	0.4	85
39	Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy. Cancer Letters, 2016, 373, 19-26.	3.2	75
40	Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB. Oncotarget, 2016, 7, 80765-80782.	0.8	16
41	The NFÎ $^{\circ}$ B inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biology and Therapy, 2014, 15, 602-611.	1.5	18
42	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biology and Therapy, 2014, 15, 570-577.	1.5	68
43	Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology. Pharmacological Reviews, 2013, 65, 1162-1197.	7.1	220
44	Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. Autophagy, 2013, 9, 208-219.	4.3	64
45	MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis. Molecular Cancer Therapeutics, 2012, 11, 154-164.	1.9	121
46	eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206. Cancer Research, 2011, 71, 2654-2663.	0.4	126
47	eEF-2 kinase, another meddler in the "Yin and Yang―of Akt–mediated cell fate?. Autophagy, 2011, 7, 660-661.	4.3	15